Kyorin to Transfer Generic Drug Operations to Co-Creation Platform with Daito

KYORIN Pharmaceutical Co.,Ltd. ( (JP:4569) ) has provided an update.

KYORIN Pharmaceutical has signed a memorandum of understanding with Daito Pharmaceutical and co-investors to advance discussions on transferring its generic drug business, excluding authorized generics, to a new entity called Pharmatech Co-creation Platform, Inc., which Daito and partners plan to establish. The transaction would also include the transfer of the Takaoka and Inami plants operated by KYORIN Pharmaceutical Group Facilities, aligning KYORIN’s strategy to concentrate resources on innovative drug development under its long-term “Vision 110” plan.

The company is responding to structural challenges in Japan’s generic drug sector, including supply instability, deteriorating profitability, and excessive competition, by shifting its generic operations to a broader co-creation platform aimed at building a sustainable pharmaceutical supply system. KYORIN and Daito intend to ensure a smooth succession that preserves employment conditions for the generic business workforce and supports stable generic drug supply, potentially reshaping KYORIN’s business portfolio and reinforcing its positioning as a new-drug-focused player while contributing to industry-wide supply stability.

More about KYORIN Pharmaceutical Co.,Ltd.

KYORIN Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company listed on the TSE Prime that develops, manufactures, and sells prescription drugs, with a strategic focus on high-value new medicines. The group also operates generic drug and production facility businesses through consolidated subsidiaries such as KYORIN Rimedio Co., Ltd. and KYORIN Pharmaceutical Group Facilities Co., Ltd., serving the domestic healthcare market.

Average Trading Volume: 105,850

Technical Sentiment Signal: Buy

Current Market Cap: Yen83.17B

For a thorough assessment of 4569 stock, go to TipRanks’ Stock Analysis page.